Clinical trial · Interventional
Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART
Eltrombopag Treatment and Analysis of Bone Marrow Environment in Patients With Prolonged Bone Marrow Toxicity After CART Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Treatment with chimeric antigen receptor-T cell (CAR-T) is successful in patients who have not responded to chemotherapy or bone marrow transplantation but it may provoke side effects and long-term complications. Early and specific side effects include cytokine release syndrome and neurological toxicity. In addition, there are also late side effects. The most prominent of which is bone marrow damage and lack of recovery of blood counts after treatment. In this study, patients with prolong aplasia after CAR-T will recieve eltrombopag to enahnce bone marrow recovery.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| B Cell Lymphoma | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
| CART Treatment | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Eltrombopag | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Eltrombopag
- description
- Patients with bone marrow aplasia for more than 30 days after CART treatment
- interventionNames
- Drug: Eltrombopag
Primary outcomes (2)
- measure
- The percentage of cellularity
- timeFrame
- up to 12 weeks (4 weeks from CART treatment and additional 8 weeks of treatment with eltrombopag)
- description
- Efficacy of eltrombopag treatment will be measured based on recovery of blood counts and recovery of bone marrow aplasia (measured as percentage of cellularity)
- measure
- Identify the mechanism for the appearance of late bone marrow toxicity
- timeFrame
- 12 weeks from CART treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Willing to participate in the study and able to sign an informed consent form. 2. Patients with B cell lymphoma or multiple myeloma who were treated with CART and demonstrated cytopenia on day 14 after CART administration. Cytopenia definition: absolute neutrophil count \<500 neutrophils/ul and/or platelets \<50,000 mm3 3. Bone marrow demonstrates hypoplasia (cellularity less than 30%) 14 days after CART administration. \- Exclusion Criteria: 1. Creatine \> 2.5 mg / dL 2. Disorder in liver enzymes: bilirubin above 2 mg/dl , AST or ALT 5 times the normal. 3. Active infection 4. Active hemophagocytic syndrome 5. Evidence of a viral or pharmacological disease that causes bone marrow injury 6. Susceptibility to eltrombopag 7. Evidence of disease in the bone marrow -
References
Publications (0)
Data not yet available